Journal Report

BIODRUGS

Download PDF
Journal Information
Journal Title
BIODRUGS
Publisher
ADIS INT LTD
ISSN
1173-8804
E-ISSN
1179-190X
Database
Clarivate
Domain
Health Sciences, Life Sciences, Social Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Risk of Major Cardiovascular Events in Patients with Psoriasis, Psoriatic Arthritis, and/or Other Forms of Spondyloarthritis: A Cohort of 72,291 Biologic New Users
Laetitia Penso, Mounya Abboud, Mahmoud Zureik et al.
2026-10-30
Sustained Efficacy and Safety of Mirikizumab Through 152 Weeks in Chinese Patients with Moderately to Severely Active Crohn’s Disease: A Subpopulation Analysis of the VIVID-1 and VIVID-2 Phase 3 Trials
Xiang Gao, Qian Cao, Xiaowei Liu et al.
2026-10-28
Correction: Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field
Matthew J. Slarve, Christine Tkaczyk, Michael P. Doyle et al.
2026-10-27
IL-6 Blockade for Antibody-Mediated Transplant Rejection: What Does the Evidence Say?
Mehmet Kanbay, Sidar Copur, Can Altunbulakli et al.
2026-10-23
Incidence and Risk Factors of Treatment-Emergent Eczematous Reactions in Patients with Psoriasis Treated with Biologics: A Systematic Review and Meta-Analysis
Yifei Feng, Yan Lu
2026-10-16
From Reflection to Implementation: Tailored Clinical Development of a Pembrolizumab Biosimilar Candidate
Björn Capsius, Marija Pesic, Ravil Niyazov et al.
2026-9-19
Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects
Qiang Chen
2026-9-17
Biologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases
Liyan Qiu, Jonas Torbjörn Ungerbäck, Eric Paul Bennett et al.
2026-9-14
Biosimilars: A Virtuous Cycle of Sustainability and Innovation
Fernando de Mora, Vicente Merino-Bohórquez, Rosario García-Vicuña et al.
2026-9-14
Beyond the Prevention of Anti-drug Antibody Formation with Uricase Therapy: Mechanistic Roles of DMARDs in Modifying Gout Flare Risk
Ted R. Mikuls, Tuhina Neogi, Angelo Gaffo
2026-9-14
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: October 31, 2026 23:01